Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors

Pediatric Solid Tumors Clinical Trial

Official title:
Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors

Status Recruiting

Clinical Trial Summary

Single Cohort A(GAIA-102 alone): Confirm the safety of GAIA-102 alone for refractory/relapse neuroblastoma or pediatric solid tumors with lung metastases, and decide recommended dose for Phase II. Cohort B(GAIA-102 with Dinutuximab): Confirm the safety of GAIA-102 with Dinutuximab, Filgrastim, Teceleukin combination for refractory/relapse neuroblastoma and decide recommended dose for Phase II. Cohort C(GAIA-102 with Nivolumab):Confirm the safety of GAIA-102(Follow the recommended doses in Cohort A) with Nivolumab. Cohort C(GAIA-102 with Nivolumab):Confirm the safety of GAIA-102(Follow the recommended doses in Cohort A) with Nivolumab

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05608148
Study type	Interventional
Source	Kyushu University
Contact
Status	Recruiting
Phase	Phase 1
Start date	October 26, 2022
Completion date	August 25, 2027

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02747537` - Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan	Phase 2
Recruiting	`NCT06171971` - Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
Completed	`NCT01049841` - Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors	Phase 1
Completed	`NCT00990912` - A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)	Phase 1/Phase 2
Recruiting	`NCT01050296` - Molecular Analysis Of Solid Tumors
Recruiting	`NCT04773808` - Molecular Characterization of Genetic Alterations in Pediatric Solid Tumors